6-K ·Filed Aug 24, 2026

GSK

GSK plc
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago SEC0001654954-26-007810
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine PDMR sale with no material impact. Monitor for any cluster of insider selling by multiple executives, which would be a more meaningful signal. The sale is not indicative of operational issues at GSK.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
GSK ▼ -2.05% at T+20d
NEUTRAL call ✗ call lost -2.05% · α vs SPY -3.35% · entry $51.78 → $50.72
Next anchor: T+60d in 7w
Latest observation: T+27 -5.12% FF3 residual α
Entry anchored
Aug 24, 10:35 AM ET
via 1-min bar
T+1d
+0.56%
call +0.56% · α +0.24%
$52.07
settled 5w ago
T+5d
-2.95%
call -2.95% · α -3.42%
$50.25
settled 5w ago
T+20d
-2.05%
call -2.05% · α -3.35%
$50.72
settled 10d ago
T+60d
—
call — · α —
—
in 7w

Price Chart

Loading chart...

Executive Summary

GSK's US President, Maya Martinez-Davis, sold a total of 44,397 American Depositary Shares (ADS) over two days (Aug 20-21, 2026) at approximately $52.14 per share, for total proceeds of about $2.3 million. This is a routine insider sale by a senior executive and does not signal any change in company fundamentals or strategy.

Key Facts

  • Maya Martinez-Davis, President US of GSK, sold 3,916 ADS on Aug 20, 2026 at $52.14.
  • Maya Martinez-Davis sold 40,481 ADS on Aug 21, 2026 at a weighted average price of $52.1437.
  • Total ADS sold: 44,397, total proceeds approximately $2.3 million.
  • The sales were executed on the New York Stock Exchange and reported via Form 6-K on Aug 24, 2026.

Financial Impact

Total insider sale proceeds of approximately $2.3 million, representing a de minimis fraction of GSK's $106.1B market cap.

Risk Factors

  • Insider selling by a senior US executive could be misinterpreted by the market as a lack of confidence, though the amount is trivial relative to market cap.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007810
Document: 0001654954-26-007810-index-headers.html0001654954-26-007810
Document: 0001654954-26-007810-index.html0001654954-26-007810
Document: 0001654954-26-007810.txt0001654954-26-007810
42 reports for GSK
Performance horizon
69% Hit rate 11 of 16 directional calls best @ T+60▲ +7.85%Jun 16, 2026
Filters
Rows
Reports for GSK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 5/10
$50.01 $50.22▲ +0.42%▼ −0.40%$47.03 (−5.96%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 11, 2026
21d ago
6-K
NEUTRAL ★ 1/10
$48.13 $50.22▲ +4.34%▲ +4.56%$47.03 (−2.29%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 1/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 3/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 6/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 1/10
$51.43 $50.44▼ −1.92%▼ −1.80%$47.03 (−8.56%)
Aug 24, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$51.78 $50.25▼ −2.95%▼ −3.42%$47.03 (−9.17%)
Showing 10 of 42

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access